Plain-English translation of NCT04970472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Toulouse University Hospital want to better understand bladder cancer by studying samples from patients — including blood, urine, stool, and saliva, as well as tumor tissue. Scientists believe that bacteria naturally living in the bladder (called the microbiome) may play a role in how the disease develops and how well treatments like immunotherapy or chemotherapy work.
Recent research suggests that imbalances in bladder bacteria are linked to bladder cancer and may affect how well standard treatments work. By collecting and studying these samples, researchers hope to learn whether the microbiome influences treatment success and can help guide future care decisions.
You likely qualify if…
You likely don't qualify if…
You will provide small samples of blood (about one tablespoon), urine, stool, and saliva before any bladder surgery. If you have a tumor removed as part of your standard care, doctors may also collect a small tissue sample to study. After that, you'll continue with your regular follow-up appointments as normally scheduled — no extra visits are needed for this study. Researchers will track your health outcomes for up to 5 years.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France
Enrollment target
~1,000 participants
Started
November 2021
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mathieu Roumiguie, MD, PhD
University Hospital, Toulouse
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.